Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
462-01-002 ISMRM Abstract

Assessment of glioma biomarkers using amide proton transfer weighted MRI with and without fluid suppression

Primary: Neuro - Tumors
Secondary: Contrast Mechanisms - CEST / APT / NOE
462-01-002 · Contrast Mechanisms Potpourri Including Registered/Clinical Abstracts · Tuesday, 12 May, 8:20 AM–9:15 AM · Digital Posters Row C
Keywords: Glioma APT Fluid suppression Neuroimaging Biomarkers Brain Tumor Imaging
Accepted
Malte Knutsson 1, Tim Salomonsson1, Anina Seidemo1, Faris Durmo1, Anna Rydelius1,2, Xavier S Sarda3, Patrick Liebig4,5, Mattias Belting6, Johan Bengzon7, Peter C van Zijl8,9, Linda Knutsson9,10,11, Pia Maly Sundgren1,12,13
1Diagnostic Radiology, Lund University, Lund, Sweden
2Department of Neurology, Lund University Hospital, Lund, Sweden
3Department of Pathology, Lund University Hospital, Lund, Sweden
4Siemens Healthineers AG, Erlangen, Germany
5MR Application Predevelopment, Siemens Healthineers, Erlangen, Germany
6Department of Oncology, Lund University Hospital, Lund, Sweden
7Department of Neurosurgery, Lund University Hospital, Lund, Sweden
8Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, United States of America
9F. M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research Institute, Baltimore, United States of America
10Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, United States of America
11Medical Radiation Physics, Clinical Sciences Lund, Lund University, Lund, Sweden
12Department of Medical Imaging and Physiology, Lund University Hospital, Lund, Sweden
13Medicinska fakulteten, Lund University Bioimaging Centre, Lund University, Lund, Sweden
Presenting Author: Malte Knutsson

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Karsy M, Guan J, Cohen AL, Jensen RL, Colman H. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Current Neurology and Neuroscience Reports. 2017;17(2):19. DOI: 10.1007/s11910-017-0722-5. [doi]
2. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000;143(1):79-87. DOI: 10.1006/jmre.1999.1956 [doi]
3. Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med. 2003;50(6):1120-6. DOI: 10.1002/mrm.10651 [doi]
4. Su C, Liu C, Zhao L, Jiang J, Zhang J, Li S, et al. Amide Proton Transfer Imaging Allows Detection of Glioma Grades and Tumor Proliferation: Comparison with Ki-67 Expression and Proton MR Spectroscopy Imaging. AJNR Am J Neuroradiol. 2017;38(9):1702-9. DOI: 10.3174/ajnr.A5301 [doi]
5. Jiang S, Zou T, Eberhart CG, Villalobos MAV, Heo HY, Zhang Y, et al. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Magn Reson Med. 2017;78(3):1100-9 .DOI: 10.1002/mrm.26820 [doi]
6. Durmo F, Lätt J, Rydelius A, Englund E, Salomonsson T, Liebig P, et al. Role of Amide Proton Transfer Weighted MRI in Predicting MGMTp Methylation Status, p53-Status, Ki-67 Index, IDH-Status, and ATRX Expression in WHO Grade 4 High Grade Glioma. Tomography. 2025;11(6):64. DOI: 10.3390/tomography11060064 [doi]
7. Paech D, Windschuh J, Oberhollenzer J, Dreher C, Sahm F, Meissner JE, et al. Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. Neuro Oncol. 2018;20(12):1661-71. DOI: 10.1093/neuonc/noy073 [doi]
8. Jiang S, Rui Q, Wang Y, Heo HY, Zou T, Yu H, et al. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. Eur Radiol. 2018;28(5):2115-23. DOI: 10.1007/s00330-017-5182-4 [doi]
9. Joo B, Han K, Ahn SS, Choi YS, Chang JH, Kang SG, et al. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma. Eur Radiol. 2019;29(12):6643-52. DOI: 10.1007/s00330-019-06203-x [doi]
10. Su L, Gao P, Lin S, Wu B, Qin W, Lin Y, et al. Predicting O6-Methylguanine-DNA Methyltransferase Protein Expression in Primary Low- and High-Grade Gliomas Using Certain Qualitative Characteristics of Amide Proton Transfer-Weighted Magnetic Resonance Imaging. World Neurosurgery. 2018;116:e814-e23. DOI: 10.1016/j.wneu.2018.05.100 [doi]
11. Schure JR, Casagranda S, Sedykh M, Liebig P, Papageorgakis C, Mancini L, et al. Fluid suppression in amide proton transfer-weighted (APTw) CEST imaging: New theoretical insights and clinical benefits. Magn Reson Med. 2024;91(4):1354-67. DOI: 10.1002/mrm.29915 [doi]
12. Zhou J, Zaiss M, Knutsson L, Sun PZ, Ahn SS, Aime S, et al. Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors. Magn Reson Med. 2022;88(2):546-74. DOI: 10.1002/mrm.29241 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/462-01-002